Paper · 20179196

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Turner N and 14 others. Cancer Res, 2010. Cited by 591 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Papers, record 20179196. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20179196

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.; PubMed
Journal: Cancer Res; PubMed
Year: 2010; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/20179196/; PubMed
DOI: https://doi.org/10.1158/0008-5472.can-09-3746; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC2832818/; PubMed
The journal: https://conductscience.org/library/journal-index/2984705R; PubMed
Citations, by iCite: 591; iCite
Relative citation ratio, by iCite: 13.2; iCite
Revised in PubMed: 2025-05-29; PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Turner N	Nicholas
2	Pearson A	Alex
3	Sharpe R	Rachel
4	Lambros M	Maryou
5	Geyer F	Felipe
6	Lopez-Garcia MA	Maria A
7	Natrajan R	Rachael
8	Marchio C	Caterina
9	Iorns E	Elizabeth
10	Mackay A	Alan

1 to 10 of 15Source PubMed

See all 15 authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Agents, Hormonal	Major topic
Breast Neoplasms	Major topic
Receptor, Fibroblast Growth Factor, Type 1	Major topic
Cell Adhesion
Cell Growth Processes
Cell Line, Tumor
Drug Resistance, Neoplasm
Estradiol
Female
Fibroblast Growth Factor 2
Fulvestrant
Gene Amplification
Gene Silencing
Humans
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Phosphatidylinositol 3-Kinases
Phosphorylation
RNA, Messenger
Receptors, Estrogen
Tamoxifen

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
A10038	Cancer Research UK	United Kingdom		PubMed
BREAST CANCER NOW RESEARCH CENTRE	Breast Cancer Now	United Kingdom		PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	20,836,672	Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.	https://conductscience.org/library/papers/20836672

Source PubMed

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	18,089,785	Integrated profiling of basal and luminal breast cancers.	Cancer Res	2007	https://conductscience.org/library/papers/18089785	PubMed
2	17,397,528	FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.	Breast Cancer Res	2007	https://conductscience.org/library/papers/17397528	PubMed
3	10,086,345	Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes.	Oncogene	1999	https://conductscience.org/library/papers/10086345	PubMed
4	19,479,727	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.	J Pathol	2009	https://conductscience.org/library/papers/19479727	PubMed
5	17,178,857	Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer.	Cancer Res	2006	https://conductscience.org/library/papers/17178857	PubMed
6	19,169,812	A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines.	Breast Cancer Res Treat	2009	https://conductscience.org/library/papers/19169812	PubMed
7	17,401,012	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.	J Clin Oncol	2007	https://conductscience.org/library/papers/17401012	PubMed
8	19,147,748	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.	Clin Cancer Res	2009	https://conductscience.org/library/papers/19147748	PubMed
9	19,688,261	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.	Breast Cancer Res Treat	2010	https://conductscience.org/library/papers/19688261	PubMed
10	15,863,033	Fibroblast growth factor signaling in tumorigenesis.	Cytokine Growth Factor Rev	2005	https://conductscience.org/library/papers/15863033	PubMed

1 to 10 of 47

See all 47 references

Cited by382

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 591 citations.

PMID	Title	Journal	Year	In Papers	Source
42,845,797	Extreme ESR1 Polyclonality, Mutation Dynamics, and Effects on Treatment Outcomes in Patients with ER+ Metastatic Breast Cancer.	Res Sq	2026	https://conductscience.org/library/papers/42845797	PubMed
42,824,816	FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement.	Front Immunol	2026	https://conductscience.org/library/papers/42824816	PubMed
42,820,289	Toward targeted therapeutics for lobular breast cancer.	J Clin Invest	2026	https://conductscience.org/library/papers/42820289	PubMed
42,713,707	Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.	J Pathol	2026	https://conductscience.org/library/papers/42713707	PubMed
42,658,196	Systematic analysis of network-driven adaptive resistance to CDK4/6 and oestrogen receptor inhibition using meta-dynamic network modelling.	Elife	2026	https://conductscience.org/library/papers/42658196	PubMed
42,617,046	FGFR1 Suppresses STING-Mediated Interferon Response in Endocrine Therapy-Resistant Breast Cancer.	Cancer Res Commun	2026	https://conductscience.org/library/papers/42617046	PubMed
42,524,362	Efficacy of Pazopanib for a Patient with FGFR1-Amplified Breast Cancer: A Case Report.	Case Rep Oncol	2026	https://conductscience.org/library/papers/42524362	PubMed
42,427,700	A High-Fidelity and Ancestrally Inclusive Patient-Derived Organoid Platform Resolves Cancer Cell Plasticity in Uterine Carcinosarcoma.	bioRxiv	2026	https://conductscience.org/library/papers/42427700	PubMed
42,082,487	Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.	Nat Commun	2026	https://conductscience.org/library/papers/42082487	PubMed
42,020,778	CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.	Br J Cancer	2026	https://conductscience.org/library/papers/42020778	PubMed

1 to 10 of 382

See all 382 cited by

Genes24

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
CCND1	595	PubTator's text mining	https://conductscience.org/library/genes/595	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
EREG	2,069	PubTator's text mining	https://conductscience.org/library/genes/2069	NCBI Gene
ESR1	2,099	PubTator's text mining	https://conductscience.org/library/genes/2099	NCBI Gene
FGF2	2,247	PubTator's text mining	https://conductscience.org/library/genes/2247	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
FGFR2	2,263	PubTator's text mining	https://conductscience.org/library/genes/2263	NCBI Gene
FRS2	10,818	PubTator's text mining	https://conductscience.org/library/genes/10818	NCBI Gene
FUT4	2,526	PubTator's text mining	https://conductscience.org/library/genes/2526	NCBI Gene

1 to 10 of 24

See all 24 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20179196

GET https://conductscience.org/api/papers/v1/20179196/references?page=2

API reference For AI assistants